ARCT
Arcturus Therapeutics Holdings Inc

5,493
Mkt Cap
$188.44M
Volume
752,062.00
52W High
$24.17
52W Low
$5.85
PE Ratio
-2.78
ARCT Fundamentals
Price
$6.63
Prev Close
$6.72
Open
$6.75
50D MA
$7.40
Beta
1.76
Avg. Volume
418,124.00
EPS (Annual)
-$2.40
P/B
0.88
Rev/Employee
$605,594.59
$38.03
Loading...
Loading...
News
all
press releases
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial
B. Riley Financial upgraded Arcturus Therapeutics to a "strong-buy" rating in a research report on Tuesday...
MarketBeat·17h ago
News Placeholder
More News
News Placeholder
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are currently covering the stock...
MarketBeat·20h ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated at B. Riley Financial
B. Riley Financial started coverage on Arcturus Therapeutics in a research report on Wednesday. They issued a "buy" rating and a $22.00 target price for the company...
MarketBeat·3d ago
News Placeholder
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
Arcturus Therapeutics (NASDAQ:ARCT) Chief Executive Officer Joe Payne told investors at the Leerink Partners Global Healthcare Conference that the company has advanced its inhaled messenger RNA...
MarketBeat·9d ago
News Placeholder
Q1 EPS Forecast for Arcturus Therapeutics Reduced by Analyst
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Equities researchers at HC Wainwright reduced their Q1 2026 EPS estimates for shares of Arcturus Therapeutics in a research note...
MarketBeat·15d ago
News Placeholder
Citigroup Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price
Citigroup reduced their price objective on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday...
MarketBeat·15d ago
News Placeholder
Arcturus Therapeutics to Attend Upcoming Investor Conference
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Business Wire·16d ago
News Placeholder
ARK Investment Management LLC Boosts Position in Arcturus Therapeutics Holdings Inc. $ARCT
ARK Investment Management LLC increased its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 9.2% in the 3rd quarter, according to the company in its most...
MarketBeat·16d ago
News Placeholder
Citigroup Issues Positive Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price
Citigroup upped their target price on shares of Arcturus Therapeutics from $7.00 to $8.00 and gave the company a "neutral" rating in a report on Wednesday...
MarketBeat·16d ago
News Placeholder
Piper Sandler Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $25.00
Piper Sandler dropped their price target on Arcturus Therapeutics from $72.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday...
MarketBeat·17d ago
<
1
2
...
>

Latest ARCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.